Neville Rodie & Shaw Inc. Grows Stock Position in Boston Scientific Corporation $BSX

Key Points

• Neville Rodie & Shaw Inc. increased its stake in Boston Scientific by 95.9% during Q2, owning 45,460 shares worth approximately $4.88 million.
• Insider activity included EVP Joseph Michael Fitzgerald selling 50,000 shares for around $5.27 million, reflecting a 21.90% decrease in his ownership.
• Several analysts have raised their target prices for Boston Scientific, with Truist Financial and Oppenheimer both setting targets at $125, maintaining a overall consensus rating of "Buy."

Neville Rodie & Shaw Inc. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 95.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 45,460 shares of the medical equipment provider's stock after buying an additional 22,255 shares during the period. Neville Rodie & Shaw Inc.'s holdings in Boston Scientific were worth $4,883,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. HM Payson & Co. increased its stake in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after purchasing an additional 98 shares during the period. Park Square Financial Group LLC increased its stake in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the period. HHM Wealth Advisors LLC increased its stake in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after purchasing an additional 103 shares during the period. Rise Advisors LLC increased its stake in Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 103 shares during the period. Finally, Forum Financial Management LP increased its stake in Boston Scientific by 0.8% in the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after purchasing an additional 112 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president owned 178,342 shares of the company's stock, valued at $18,802,597.06. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 in the last three months. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on BSX. Truist Financial increased their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Raymond James Financial increased their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Citigroup reissued a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Price Performance

BSX opened at $102.71 on Friday. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The business's fifty day simple moving average is $104.86 and its 200-day simple moving average is $102.26. The company has a market capitalization of $152.19 billion, a price-to-earnings ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the company earned $0.62 earnings per share. The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.